After 8 cycles of NAC, there was a significantly reduced % of CD4+CD25+CD127- FOXP3+Tregs, compared with pre-treatment levels, in patients who had a good pathological response in their tumours (Group I and II) (p = 0.033). This evidence concerns the gene FOXP3 and neoplasm.